WHO updates policy for the use of lateral flow urine lipoarabinomannan assay (LF-LAM) for diagnosing active tuberculosis in people living with HIV

Published on October 31, 2019

WHO updates policy for the use of lateral flow urine lipoarabinomannan assay (LF-LAM) for diagnosing active tuberculosis in people living with HIV

Following new evidence, WHO now recommends a broader use of urinary LAM assays for diagnosis of TB in people living with HIV.

Link to policy: https://mailchi.mp/who/who_guidance_lf-lam_plhiv

Other news

This app for tuberculosis increases odds of patients completing treatment

September 25, 2019
This app for tuberculosis increases odds of patients completing treatmentAfter the experimental intervention, only 4 percent of tuberculosis patients had unsuccessful treatment outcomes. For comparison, 13 percent of patients in a control group, who did not use the platform, didn't finish their treatment.Image: REUTERS/Sherwin Crasto SC/ - RP4DRIIEHOAAKeheala - a health platform for the tuberculos

A powerful tuberculosis drug gets a deep price cut

October 31, 2019
A powerful tuberculosis drug gets a deep price cutBy Jon CohenOct. 31, 2019 , 1:30 AMSanofi, a pharmaceutical company based in Paris, announced today it will sell the drug rifapentine at the steeply discounted price. The full course of preventive treatment with the drug will drop from $45 to $15.URL: https://www.sciencemag.org/news/2019/10/powerful-tuberculosis-drug-gets-deep-price-cut